

Pharmacogenomics Market by Product & Service (Kits & Reagents), Technology (Sequencing, PCR, Microarray), Application (Drug Discovery, Clinical Research, Personalized Medicine), Disease Area (Cancer, Neurological, Cardiovascular) - Global Forecast to 2028

Market Report | 2024-02-14 | 381 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The pharmacogenomics market is projected to reach USD 5.8 billion by 2028 from an estimated USD 3.5 billion in 2023, at a CAGR of 10.6% during the forecast period. The growth of this market can be attributed to the research and development efforts aimed at drug discovery and development, and growing focus on personalized medicines.

"The kits & reagents segment accounted for the largest share by product & service in 2022."

In 2022, the kits & reagents segment accounted for the largest share of product type in the global pharmacogenomics market. The factors such as growing demand for high quality reagents for genomics studies, increasing focus on development of personalized medicines, and growing number of research projects in the field of genomics are driving the growth of this market.

""The Asia Pacific region is growing in the pharmacogenomics market during the forecast period of 2023-2028."

The Asia Pacific region is expected to grow at the highest growth rate during the forecast period. Various factors including growing adoption of advanced sequencing technologies and booming healthcare sector are propelling the growth of pharmacogenomics market in the region.

Increased funding and investments from pharmaceutical and biotechnology companies aimed at advancing the healthcare sector are expected to propel the growth of the pharmacogenomics market in the Asia Pacific region. According to R&D Magazine, Asia has become the world's foremost region in research and development (R&D) investment, claiming over 44% of the global R&D share. The region is steadily gaining an additional half-percent share each year, and if this trend persists, it could represent more than half of all R&D investments by 2030. China is actively enhancing its R&D infrastructure and human resources capabilities,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

maintaining a consistent commitment to spending, ambition, and long-term planning. These factors are expected to contribute for the highest CAGR of the region between 2023 to 2028.

The primary interviews conducted for this report can be categorized as follows:

- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers - 45%, CXO & Directors - 30%, and Executives - 25%
- By Region: North America -30%, Europe -20%, Asia-Pacific -30%, Latin America -15% and Middle East & Africa- 5%

List of Companies Profiled in the Report:

- Illumina, Inc. (US)
- Thermo Fisher Scientific Inc. (US)
- Danaher Corporation (US)
- Laboratory Corporation of America Holdings (US)
- Charles River Laboratories (US)
- Eurofins Scientific (Luxembourg)
- Bio-Rad Laboratories, Inc. (US)
- Agilent Technologies, Inc. (US)
- BD (US)
- QIAGEN (Netherlands)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Revvity (US), IQVIA Inc. (US)
- Mesa Labs, Inc. (US)
- Medpace (US)
- MGI Tech Co., Ltd. (China)
- Takara Bio Inc. (Japan)
- PacBio (US)
- New England Biolabs (US)
- BGI (China), Novogene Co., Ltd. (China)
- SOPHiA GENETICS (Switzerland), Fios Genomics (UK)
- Personalis, Inc. (US)
- BioAI Health Inc. (US)
- NeoGenomics Laboratories (US)
- Macrogen, Inc. (South Korea.)

Research Coverage:

This research report categorizes the pharmacogenomics market by product & service (kits & reagents (sequencing kits and reagents, PCR kits and reagents, microarray kits and reagents, and other kits & reagents) and service), technology (sequencing, PCR, microarray, and other technologies), disease area (cancer, cardiovascular, neurological diseases, and other disease areas), application (personalized medicine, clinical research, and drug discovery & preclinical development), and end user (academic & research institutes, pharmaceutical & biotechnology companies, and contract research organization)

The report provides in-depth information on significant factors influencing the growth of the pharmacogenomics market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, products/services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches, mergers, and acquisitions within the pharmacogenomics market.

Key Benefits of Buying the Report:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall pharmacogenomics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

- Analysis of key drivers (growing incidence and prevalence of chronic and genetic diseases and rising investments and funding to support genomic projects), restraints (challenges in data integration and interpretation, and issues related to drug response variability), opportunities (growing usage of genomics in specialized/personalized medicine), and challenges (ethical & regulatory issues, concern related to patient privacy & data accessibility) influencing the growth of the market.
- Product & Service Development/Innovation: Detailed insights on newly launched products/services of the pharmacogenomics market
- Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the pharmacogenomics market
- Competitive Assessment: Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), BD (US), QIAGEN (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Revvity (US), IQVIA Inc. (US), Mesa Labs, Inc. (US), Medpace (US), MGI Tech Co., Ltd. (China), Takara Bio Inc. (Japan), PacBio (US), New England Biolabs (US), among others in the market.

Table of Contents:

1□INTRODUCTION□	47
1.1□STUDY OBJECTIVES□	47
1.2□MARKET DEFINITION□	47
1.2.1□INCLUSIONS AND EXCLUSIONS OF STUDY□	48
1.2.2□MARKET SEGMENTATION□	49
FIGURE 1□PHARMACOGENOMICS MARKET SCOPE□	49
1.2.3□YEARS CONSIDERED□	50
1.3□CURRENCY□	50
1.4□STAKEHOLDERS□	50
1.5□LIMITATIONS□	51
1.6□RECESSION IMPACT□	51
2□RESEARCH METHODOLOGY□	52
2.1□RESEARCH DATA□	52
FIGURE 2□RESEARCH DESIGN□	52
2.1.1□SECONDARY DATA□	53
2.1.2□PRIMARY DATA□	54
FIGURE 3□PHARMACOGENOMICS MARKET: BREAKDOWN OF PRIMARIES□	54
2.2□MARKET SIZE ESTIMATION□	55
2.2.1□BOTTOM-UP APPROACH□	55
FIGURE 4□MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2022)□	55
FIGURE 5□MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022□	56
FIGURE 6□ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS (2022)□	56
2.2.1.1□Insights from primaries□	58
FIGURE 7□MARKET VALIDATION FROM PRIMARY EXPERTS□	58
2.2.2□TOP-DOWN APPROACH□	58

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

FIGURE 8	MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH	58
2.3	GROWTH FORECAST	60
FIGURE 9	PHARMACOGENOMICS MARKET: CAGR PROJECTIONS	60
FIGURE 10	PHARMACOGENOMICS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	61
2.4	MARKET BREAKDOWN AND DATA TRIANGULATION	62
FIGURE 11	DATA TRIANGULATION METHODOLOGY	62
2.5	RESEARCH ASSUMPTIONS	63
2.6	RISK ANALYSIS	63
2.7	RECESSION IMPACT ANALYSIS	63
TABLE 1	GLOBAL INFLATION RATE PROJECTIONS, 2021-2028 (% GROWTH)	63
TABLE 2	US: HEALTH EXPENDITURE, 2019-2022 (USD MILLION)	64
TABLE 3	US: HEALTH EXPENDITURE, 2023-2030 (USD MILLION)	64
3	EXECUTIVE SUMMARY	65
FIGURE 12	PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION)	65
FIGURE 13	PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION)	66
FIGURE 14	PHARMACOGENOMICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)	66
FIGURE 15	PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2023 VS. 2028 (USD MILLION)	67
FIGURE 16	PHARMACOGENOMICS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)	68
FIGURE 17	GEOGRAPHICAL SNAPSHOT OF PHARMACOGENOMICS MARKET	69
4	PREMIUM INSIGHTS	70
4.1	PHARMACOGENOMICS MARKET OVERVIEW	70
FIGURE 18	RISING INCIDENCE OF CANCER TO SUPPORT MARKET GROWTH	70
4.2	NORTH AMERICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2022)	71
FIGURE 19	KITS & REAGENTS SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN PHARMACOGENOMICS MARKET IN 2022	71
4.3	PHARMACOGENOMICS MARKET SHARE, BY TECHNOLOGY, 2022	71
FIGURE 20	SEQUENCING SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022	71
4.4	PHARMACOGENOMICS MARKET SHARE, BY APPLICATION, 2022	72
FIGURE 21	PERSONALIZED MEDICINE SEGMENT DOMINATED MARKET IN 2022	72
4.5	PHARMACOGENOMICS MARKET SHARE, BY DISEASE AREA, 2022	72
FIGURE 22	CANCER SEGMENT ACCOUNTED FOR LARGEST SHARE OF PHARMACOGENOMICS MARKET IN 2022	72
4.6	PHARMACOGENOMICS MARKET SHARE, BY END USER, 2022	73
FIGURE 23	ACADEMIC & RESEARCH INSTITUTES SEGMENT DOMINATED MARKET IN 2022	73
4.7	PHARMACOGENOMICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	73
FIGURE 24	ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH DURING FORECAST PERIOD	73
5	MARKET OVERVIEW	74
5.1	INTRODUCTION	74
5.2	MARKET DYNAMICS	74
FIGURE 25	PHARMACOGENOMICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	74
TABLE 4	PHARMACOGENOMICS MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES	75
5.2.1	DRIVERS	76
5.2.1.1	Growing incidence and prevalence of chronic and genetic diseases	76
FIGURE 26	NUMBER OF PEOPLE 65 OR OLDER WITH ALZHEIMER'S DEMENTIA, 2023	76
5.2.1.2	Rising investments and funding to support genomics projects	77
5.2.1.3	Rising incidence of cancer	78
TABLE 5	CANCER INCIDENCE, 2020 VS. 2040	79
TABLE 6	CANCER PGX-RELATED PHARMACOGENES, DRUG PATHWAYS, AND CANCER DRUGS WITH SIDE EFFECTS	80

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.2.1.4 Increasing collaborations and partnerships between key players and research institutes 80
TABLE 7 COLLABORATIONS AND PARTNERSHIPS BETWEEN KEY PLAYERS AND RESEARCH INSTITUTES 81

5.2.1.5 Increasing focus on translational approach to optimize drug development processes 83

5.2.2 RESTRAINTS 84

5.2.2.1 Challenges in data integration and interpretation 84

5.2.2.2 Issues related to drug response variabilities 84

5.2.3 OPPORTUNITIES 84

5.2.3.1 Use of genomics in specialized/personalized medicine 84

5.2.3.2 AI in pharmacogenomics 85

5.2.3.3 Increasing cost-effectiveness of pharmacogenomics testing 86

5.2.4 CHALLENGES 87

5.2.4.1 Ethical and regulatory hurdles 87

5.2.4.2 Growing concerns related to patient privacy and data access 87

5.3 TECHNOLOGY ANALYSIS 88

5.3.1 SEQUENCING 88
TABLE 8 COMPARISON OF SANGER SEQUENCING AND NGS 88

5.3.2 PCR 89
TABLE 9 COMPARISON OF PCR TECHNOLOGIES 89

5.3.3 MICROARRAY 89

5.4 VALUE CHAIN ANALYSIS 90
FIGURE 27 PHARMACOGENOMICS MARKET: VALUE CHAIN ANALYSIS 92

5.5 SUPPLY CHAIN ANALYSIS 92
FIGURE 28 PHARMACOGENOMICS MARKET: SUPPLY CHAIN ANALYSIS 93

5.6 REGULATORY LANDSCAPE 94

5.6.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 95
TABLE 13 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96

5.6.2 REGULATORY SCENARIO 96
TABLE 14 PHARMACOGENOMICS MARKET: REGULATORY SCENARIO 96

5.7 ECOSYSTEM ANALYSIS 99

5.7.1 PHARMACOGENOMICS PRODUCT VENDORS 99
TABLE 15 PHARMACOGENOMICS PRODUCT VENDORS: ROLE IN ECOSYSTEM 100

5.7.2 PHARMACOGENOMICS SERVICE VENDORS 100
TABLE 16 PHARMACOGENOMICS SERVICE VENDORS: ROLE IN ECOSYSTEM 100

5.7.3 PHARMACOGENOMICS END USERS 101
TABLE 17 PHARMACOGENOMICS END USERS: ROLE IN ECOSYSTEM 101

5.7.4 PHARMACOGENOMICS REGULATORY BODIES 101
TABLE 18 PHARMACOGENOMICS REGULATORY BODIES: ROLE IN ECOSYSTEM 102

5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS 102
FIGURE 29 REVENUE SHIFT AND NEW REVENUE POCKETS 103

5.9 PRICING ANALYSIS 103

5.9.1 AVERAGE SELLING PRICE OF PHARMACOGENOMICS PRODUCTS, BY KEY PLAYER 104
TABLE 19 AVERAGE SELLING PRICE OF PHARMACOGENOMICS PRODUCTS, BY KEY PLAYER (2022) 104

5.9.2 AVERAGE SELLING PRICE OF PHARMACOGENOMICS PRODUCTS, BY REGION 105
TABLE 20 AVERAGE SELLING PRICE OF PHARMACOGENOMICS PRODUCTS, BY REGION (2022) 105

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.9.3	AVERAGE SELLING PRICE TREND ANALYSIS	105
FIGURE 30	GENOME SEQUENCING PRICING TREND	105
5.10	KEY CONFERENCES AND EVENTS IN 2023-2024	106
TABLE 21	PHARMACOGENOMICS MARKET: LIST OF CONFERENCES AND EVENTS	106
5.11	PORTER'S FIVE FORCES ANALYSIS	107
TABLE 22	PHARMACOGENOMICS MARKET: PORTER'S FIVE FORCES ANALYSIS	107
5.11.1	THREAT OF NEW ENTRANTS	108
5.11.2	THREAT OF SUBSTITUTES	108
5.11.3	BARGAINING POWER OF SUPPLIERS	108
5.11.4	BARGAINING POWER OF BUYERS	108
5.11.5	INTENSITY OF COMPETITIVE RIVALRY	108
5.12	PATENT ANALYSIS	109
FIGURE 31	PATENT APPLICATIONS FOR PHARMACOGENOMICS MARKET, JANUARY 2013-DECEMBER 2023	109
TABLE 23	INDICATIVE LIST OF PATENTS IN PHARMACOGENOMICS MARKET	109
5.13	KEY STAKEHOLDERS AND BUYING CRITERIA	111
5.13.1	KEY STAKEHOLDERS IN BUYING PROCESS	111
FIGURE 32	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PHARMACOGENOMICS PRODUCTS AND SERVICES	111
TABLE 24	INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PHARMACOGENOMICS PRODUCTS AND SERVICES	111
5.13.2	BUYING CRITERIA FOR PHARMACOGENOMICS MARKET	112
FIGURE 33	BUYING CRITERIA FOR PHARMACOGENOMICS PRODUCTS	112
TABLE 25	BUYING CRITERIA FOR PHARMACOGENOMICS PRODUCTS AND SERVICES, BY END USER	113
6	PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE	114
6.1	INTRODUCTION	115
TABLE 26	PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION)	115
6.2	KITS & REAGENTS	115
TABLE 27	PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION)	116
TABLE 28	PHARMACOGENOMICS KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)	116
TABLE 29	NORTH AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	117
TABLE 30	EUROPE: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	117
TABLE 31	ASIA PACIFIC: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	118
TABLE 32	LATIN AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	118
TABLE 33	MIDDLE EAST & AFRICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)	119
TABLE 34	MIDDLE EAST: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)	119
6.2.1	SEQUENCING KITS & REAGENTS	119
6.2.1.1	Development of new sequencing technologies to drive market	119
TABLE 35	SEQUENCING KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)	120
TABLE 36	NORTH AMERICA: SEQUENCING KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	120
TABLE 37	EUROPE: SEQUENCING KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	121
TABLE 38	ASIA PACIFIC: SEQUENCING KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	121
TABLE 39	LATIN AMERICA: SEQUENCING KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	122
TABLE 40	MIDDLE EAST & AFRICA: SEQUENCING KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)	122
TABLE 41	MIDDLE EAST: SEQUENCING KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)	122
6.2.2	PCR KITS & REAGENTS	123
6.2.2.1	Ensures standardized and reliable identification of genetic variants related to drug metabolism	123
TABLE 42	PCR KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION)	123
TABLE 43	NORTH AMERICA: PCR KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	124
TABLE 44	EUROPE: PCR KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	124

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 45 □ ASIA PACIFIC: PCR KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 125

TABLE 46 □ LATIN AMERICA: PCR KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 125

TABLE 47 □ MIDDLE EAST & AFRICA: PCR KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION) □ 126

TABLE 48 □ MIDDLE EAST: PCR KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION) □ 126

6.2.3 □ MICROARRAY KITS & REAGENTS □ 126

6.2.3.1 □ Cost-effectiveness and high-throughput capabilities to support adoption □ 126

TABLE 49 □ MICROARRAY KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION) □ 127

TABLE 50 □ NORTH AMERICA: MICROARRAY KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 127

TABLE 51 □ EUROPE: MICROARRAY KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 128

TABLE 52 □ ASIA PACIFIC: MICROARRAY KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 128

TABLE 53 □ LATIN AMERICA: MICROARRAY KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 129

TABLE 54 □ MIDDLE EAST & AFRICA: MICROARRAY KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION) □ 129

TABLE 55 □ MIDDLE EAST: MICROARRAY KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION) □ 129

6.2.4 □ OTHER KITS & REAGENTS □ 130

TABLE 56 □ OTHER KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION) □ 130

TABLE 57 □ NORTH AMERICA: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 131

TABLE 58 □ EUROPE: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 131

TABLE 59 □ ASIA PACIFIC: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 132

TABLE 60 □ LATIN AMERICA: OTHER KITS & REAGENTS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 132

TABLE 61 □ MIDDLE EAST & AFRICA: OTHER KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION) □ 133

TABLE 62 □ MIDDLE EAST: OTHER KITS & REAGENTS MARKET, BY REGION, 2021-2028 (USD MILLION) □ 133

6.3 □ SERVICES □ 133

6.3.1 □ SCALABILITY OF CRO SERVICES ALLOWS TAILORED SOLUTIONS □ 133

TABLE 63 □ PHARMACOGENOMICS SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION) □ 134

TABLE 64 □ NORTH AMERICA: PHARMACOGENOMICS SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 134

TABLE 65 □ EUROPE: PHARMACOGENOMICS SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 135

TABLE 66 □ ASIA PACIFIC: PHARMACOGENOMICS SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 135

TABLE 67 □ LATIN AMERICA: PHARMACOGENOMICS SERVICES MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 136

TABLE 68 □ MIDDLE EAST & AFRICA: PHARMACOGENOMICS SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION) □ 136

TABLE 69 □ MIDDLE EAST: PHARMACOGENOMICS SERVICES MARKET, BY REGION, 2021-2028 (USD MILLION) □ 136

7 □ PHARMACOGENOMICS MARKET, BY TECHNOLOGY □ 137

7.1 □ INTRODUCTION □ 138

TABLE 70 □ PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) □ 138

7.2 □ SEQUENCING □ 138

7.2.1 □ GROWING ADOPTION OF GENETIC TESTING FOR DIAGNOSIS AND TREATMENT TO DRIVE MARKET □ 138

TABLE 71 □ SEQUENCING MARKET, BY REGION, 2021-2028 (USD MILLION) □ 139

TABLE 72 □ NORTH AMERICA: SEQUENCING MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 139

TABLE 73 □ EUROPE: SEQUENCING MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 140

TABLE 74 □ ASIA PACIFIC: SEQUENCING MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 140

TABLE 75 □ LATIN AMERICA: SEQUENCING MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 141

TABLE 76 □ MIDDLE EAST & AFRICA: SEQUENCING MARKET, BY REGION, 2021-2028 (USD MILLION) □ 141

TABLE 77 □ MIDDLE EAST: SEQUENCING MARKET, BY REGION, 2021-2028 (USD MILLION) □ 141

7.3 □ PCR □ 142

7.3.1 □ INCREASED USE OF PCR FOR DRUG AND BIOMARKER DISCOVERY TO PROPEL MARKET □ 142

TABLE 78 □ PCR MARKET, BY REGION, 2021-2028 (USD MILLION) □ 143

TABLE 79 □ NORTH AMERICA: PCR MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 143

TABLE 80 □ EUROPE: PCR MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 144

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 81	ASIA PACIFIC: PCR MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	144
TABLE 82	LATIN AMERICA: PCR MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	145
TABLE 83	MIDDLE EAST & AFRICA: PCR MARKET, BY REGION, 2021-2028 (USD MILLION)	145
TABLE 84	MIDDLE EAST: PCR MARKET, BY REGION, 2021-2028 (USD MILLION)	145
7.4	MICROARRAY	146
7.4.1	MICROARRAY HELPS UNDERSTAND GENETIC BASIS OF DRUG METABOLISM	146
TABLE 85	MICROARRAY MARKET, BY REGION, 2021-2028 (USD MILLION)	146
TABLE 86	NORTH AMERICA: MICROARRAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	147
TABLE 87	EUROPE: MICROARRAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	147
TABLE 88	ASIA PACIFIC: MICROARRAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	148
TABLE 89	LATIN AMERICA: MICROARRAY MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	148
TABLE 90	MIDDLE EAST & AFRICA: MICROARRAY MARKET, BY REGION, 2021-2028 (USD MILLION)	149
TABLE 91	MIDDLE EAST: MICROARRAY MARKET, BY REGION, 2021-2028 (USD MILLION)	149
7.5	OTHER TECHNOLOGIES	149
TABLE 92	OTHER TECHNOLOGIES MARKET, BY REGION, 2021-2028 (USD MILLION)	150
TABLE 93	NORTH AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	150
TABLE 94	EUROPE: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	151
TABLE 95	ASIA PACIFIC: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	151
TABLE 96	LATIN AMERICA: OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2021-2028 (USD MILLION)	152
TABLE 97	MIDDLE EAST & AFRICA: OTHER TECHNOLOGIES MARKET, BY REGION, 2021-2028 (USD MILLION)	152
TABLE 98	MIDDLE EAST: OTHER TECHNOLOGIES MARKET, BY REGION, 2021-2028 (USD MILLION)	152
8	PHARMA GENOMICS MARKET, BY APPLICATION	153
8.1	INTRODUCTION	154
TABLE 99	PHARMA GENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION)	154
8.2	PERSONALIZED MEDICINE	154
8.2.1	INCREASING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET	154
TABLE 100	PHARMA GENOMICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021-2028 (USD MILLION)	155
TABLE 101	NORTH AMERICA: PHARMA GENOMICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021-2028 (USD MILLION)	156
TABLE 102	EUROPE: PHARMA GENOMICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021-2028 (USD MILLION)	156
TABLE 103	ASIA PACIFIC: PHARMA GENOMICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021-2028 (USD MILLION)	157
TABLE 104	LATIN AMERICA: PHARMA GENOMICS MARKET FOR PERSONALIZED MEDICINE, BY COUNTRY, 2021-2028 (USD MILLION)	157
TABLE 105	MIDDLE EAST & AFRICA: PHARMA GENOMICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021-2028 (USD MILLION)	158
TABLE 106	MIDDLE EAST: PHARMA GENOMICS MARKET FOR PERSONALIZED MEDICINE, BY REGION, 2021-2028 (USD MILLION)	158
8.3	CLINICAL RESEARCH	158
8.3.1	GROWING NUMBER OF CLINICAL TRIALS FOR PHARMA GENOMICS TO DRIVE MARKET	158
TABLE 107	PHARMA GENOMICS MARKET FOR CLINICAL RESEARCH, BY REGION, 2021-2028 (USD MILLION)	159
TABLE 108	NORTH AMERICA: PHARMA GENOMICS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)	160
TABLE 109	EUROPE: PHARMA GENOMICS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)	160
TABLE 110	ASIA PACIFIC: PHARMA GENOMICS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)	161
TABLE 111	LATIN AMERICA: PHARMA GENOMICS MARKET FOR CLINICAL RESEARCH, BY COUNTRY, 2021-2028 (USD MILLION)	161
TABLE 112	MIDDLE EAST & AFRICA: PHARMA GENOMICS MARKET FOR CLINICAL RESEARCH, BY REGION, 2021-2028 (USD MILLION)	161

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

MILLION) 162

TABLE 113 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR CLINICAL RESEARCH, BY REGION, 2021-2028 (USD MILLION) 162
8.4 DRUG DISCOVERY & PRECLINICAL DEVELOPMENT 162

8.4.1 INCREASING APPLICATIONS OF PHARMACOGENOMICS IN DRUG DISCOVERY AND DEVELOPMENT TO SUPPORT MARKET GROWTH 162

TABLE 114 PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY REGION, 2021-2028 (USD MILLION) 163

TABLE 115 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION) 163

TABLE 116 EUROPE: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION) 164

TABLE 117 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION) 164

TABLE 118 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY COUNTRY, 2021-2028 (USD MILLION) 165

TABLE 119 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY REGION, 2021-2028 (USD MILLION) 165

TABLE 120 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR DRUG DISCOVERY & PRECLINICAL DEVELOPMENT, BY REGION, 2021-2028 (USD MILLION) 165

9 PHARMACOGENOMICS MARKET, BY DISEASE AREA 166

9.1 INTRODUCTION 167

TABLE 121 PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION) 167

9.2 CANCER 167

9.2.1 INCREASING PREVALENCE OF CANCER TO DRIVE MARKET 167

TABLE 122 PHARMACOGENOMICS MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION) 168

TABLE 123 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION) 168

TABLE 124 EUROPE: PHARMACOGENOMICS MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION) 169

TABLE 125 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION) 169

TABLE 126 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR CANCER, BY COUNTRY, 2021-2028 (USD MILLION) 170

TABLE 127 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION) 170

TABLE 128 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR CANCER, BY REGION, 2021-2028 (USD MILLION) 170

9.3 CARDIOVASCULAR DISEASE 171

9.3.1 RISING DEMAND FOR PRECISION MEDICINE TO SUPPORT MARKET GROWTH 171

TABLE 129 PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2021-2028 (USD MILLION) 171

TABLE 130 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021-2028 (USD MILLION) 172

TABLE 131 EUROPE: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021-2028 (USD MILLION) 172

TABLE 132 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021-2028 (USD MILLION) 173

TABLE 133 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY, 2021-2028 (USD MILLION) 173

TABLE 134 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2021-2028 (USD MILLION) 174

TABLE 135 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2021-2028 (USD MILLION) 174

9.4 NEUROLOGICAL DISORDERS 174

9.4.1 GROWING DEMAND FOR PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH 174

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 136 PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021-2028 (USD MILLION) 175

TABLE 137 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION) 175

TABLE 138 EUROPE: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION) 176

TABLE 139 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION) 176

TABLE 140 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION) 177

TABLE 141 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021-2028 (USD MILLION) 177

TABLE 142 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2021-2028 (USD MILLION) 177

9.5 OTHER DISEASE AREAS 178

TABLE 143 PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY REGION, 2021-2028 (USD MILLION) 178

TABLE 144 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021-2028 (USD MILLION) 179

TABLE 145 EUROPE: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021-2028 (USD MILLION) 179

TABLE 146 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021-2028 (USD MILLION) 180

TABLE 147 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY COUNTRY, 2021-2028 (USD MILLION) 180

TABLE 148 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY REGION, 2021-2028 (USD MILLION) 181

TABLE 149 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR OTHER DISEASE AREAS, BY REGION, 2021-2028 (USD MILLION) 181

10 PHARMACOGENOMICS MARKET, BY END USER 182

10.1 INTRODUCTION 183

TABLE 150 PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION) 183

10.2 ACADEMIC & RESEARCH INSTITUTES 183

10.2.1 INCREASING RESEARCH ACTIVITIES AND FUNDING TO DRIVE GROWTH 183

TABLE 151 PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION) 184

TABLE 152 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) 184

TABLE 153 EUROPE: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) 185

TABLE 154 ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) 185

TABLE 155 LATIN AMERICA: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021-2028 (USD MILLION) 186

TABLE 156 MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION) 186

TABLE 157 MIDDLE EAST: PHARMACOGENOMICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021-2028 (USD MILLION) 186

10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 187

10.3.1 GROWING STRATEGIC ALLIANCES FOR DRUG DEVELOPMENT AND PERSONALIZED MEDICINE TO PROPEL MARKET 187

TABLE 158 PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION) 188

TABLE 159 NORTH AMERICA: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) 188

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 160 □ EUROPE: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) □ 189

TABLE 161 □ ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) □ 189

TABLE 162 □ LATIN AMERICA: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2028 (USD MILLION) □ 190

TABLE 163 □ MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION) □ 190

TABLE 164 □ MIDDLE EAST: PHARMACOGENOMICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021-2028 (USD MILLION) □ 190

10.4 □ CONTRACT RESEARCH ORGANIZATIONS □ 191

10.4.1 □ INCREASING OUTSOURCING TREND IN GENOMICS FIELD TO PROPEL MARKET □ 191

TABLE 165 □ PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION) □ 191

TABLE 166 □ NORTH AMERICA: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION) □ 192

TABLE 167 □ EUROPE: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION) □ 192

TABLE 168 □ ASIA PACIFIC: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION) □ 193

TABLE 169 □ LATIN AMERICA: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021-2028 (USD MILLION) □ 193

TABLE 170 □ MIDDLE EAST & AFRICA: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION) □ 194

TABLE 171 □ MIDDLE EAST: PHARMACOGENOMICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021-2028 (USD MILLION) □ 194

11 □ PHARMACOGENOMICS MARKET, BY REGION □ 195

11.1 □ INTRODUCTION □ 196

TABLE 172 □ PHARMACOGENOMICS MARKET, BY REGION, 2021-2028 (USD MILLION) □ 196

11.2 □ NORTH AMERICA □ 196

FIGURE 34 □ NORTH AMERICA: PHARMACOGENOMICS MARKET SNAPSHOT □ 197

TABLE 173 □ NORTH AMERICA: PHARMACOGENOMICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) □ 197

TABLE 174 □ NORTH AMERICA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) □ 198

TABLE 175 □ NORTH AMERICA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION) □ 198

TABLE 176 □ NORTH AMERICA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) □ 199

TABLE 177 □ NORTH AMERICA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □ 199

TABLE 178 □ NORTH AMERICA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION) □ 200

TABLE 179 □ NORTH AMERICA: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION) □ 200

11.2.1 □ US □ 201

11.2.1.1 □ US dominates North American pharmacogenomics market □ 201

TABLE 180 □ US: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) □ 202

TABLE 181 □ US: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION) □ 202

TABLE 182 □ US: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) □ 202

TABLE 183 □ US: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) □ 203

TABLE 184 □ US: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION) □ 203

TABLE 185 □ US: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION) □ 204

11.2.2 □ CANADA □ 204

11.2.2.1 □ Growing research activities in genomics field to drive market □ 204

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 186 CANADA: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 205

TABLE 187 CANADA: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION) 205

TABLE 188 CANADA: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 206

TABLE 189 CANADA: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 206

TABLE 190 CANADA: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION) 207

TABLE 191 CANADA: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION) 207

11.2.3 RECESSION IMPACT ON NORTH AMERICAN PHARMACOGENOMICS MARKET 208

11.3 EUROPE 208

TABLE 192 EUROPE: PHARMACOGENOMICS MARKET, BY COUNTRY, 2021-2028 (USD MILLION) 209

TABLE 193 EUROPE: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 209

TABLE 194 EUROPE: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION) 210

TABLE 195 EUROPE: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 210

TABLE 196 EUROPE: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 211

TABLE 197 EUROPE: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION) 211

TABLE 198 EUROPE: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION) 212

11.3.1 GERMANY 212

11.3.1.1 Growing strategic alliances among industry players and research institutes to support market growth 212

TABLE 199 GERMANY: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 213

TABLE 200 GERMANY: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION) 213

TABLE 201 GERMANY: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 214

TABLE 202 GERMANY: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 214

TABLE 203 GERMANY: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION) 215

TABLE 204 GERMANY: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION) 215

11.3.2 UK 216

11.3.2.1 Increasing government funding for genomics projects to propel market 216

TABLE 205 UK: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 217

TABLE 206 UK: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION) 217

TABLE 207 UK: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 218

TABLE 208 UK: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 218

TABLE 209 UK: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION) 219

TABLE 210 UK: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION) 219

11.3.3 FRANCE 219

11.3.3.1 Increasing government initiatives to boost market growth 219

TABLE 211 FRANCE: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 220

TABLE 212 FRANCE: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION) 220

TABLE 213 FRANCE: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 221

TABLE 214 FRANCE: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 221

TABLE 215 FRANCE: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION) 222

TABLE 216 FRANCE: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION) 222

11.3.4 ITALY 223

11.3.4.1 Favorable funding programs to support market growth 223

TABLE 217 ITALY: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 223

TABLE 218 ITALY: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION) 224

TABLE 219 ITALY: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 224

TABLE 220 ITALY: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 225

TABLE 221 ITALY: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION) 225

TABLE 222 ITALY: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION) 226

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.3.5 SPAIN 226

11.3.5.1 Government funding for research in pharmacogenomics and precision medicine to drive market 226

TABLE 223 SPAIN: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 227

TABLE 224 SPAIN: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION) 227

TABLE 225 SPAIN: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 228

TABLE 226 SPAIN: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 228

TABLE 227 SPAIN: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION) 228

TABLE 228 SPAIN: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION) 229

11.3.6 REST OF EUROPE 229

TABLE 229 REST OF EUROPE: PHARMACOGENOMICS MARKET, BY PRODUCT & SERVICE, 2021-2028 (USD MILLION) 230

TABLE 230 REST OF EUROPE: PHARMACOGENOMICS KITS & REAGENTS MARKET, BY TYPE, 2021-2028 (USD MILLION) 230

TABLE 231 REST OF EUROPE: PHARMACOGENOMICS MARKET, BY TECHNOLOGY, 2021-2028 (USD MILLION) 231

TABLE 232 REST OF EUROPE: PHARMACOGENOMICS MARKET, BY APPLICATION, 2021-2028 (USD MILLION) 231

TABLE 233 REST OF EUROPE: PHARMACOGENOMICS MARKET, BY DISEASE AREA, 2021-2028 (USD MILLION) 232

TABLE 234 REST OF EUROPE: PHARMACOGENOMICS MARKET, BY END USER, 2021-2028 (USD MILLION) 232

11.3.7 RECESSION IMPACT ON EUROPEAN PHARMACOGENOMICS MARKET 233

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Pharmacogenomics Market by Product & Service (Kits & Reagents), Technology (Sequencing, PCR, Microarray), Application (Drug Discovery, Clinical Research, Personalized Medicine), Disease Area (Cancer, Neurological, Cardiovascular) - Global Forecast to 2028

Market Report | 2024-02-14 | 381 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

2026-03-04

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com